OPKO Health, Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $151.7 million, a decrease of 13% from $173.6 million in the same period last year. The decline was primarily driven by a 21% drop in revenue from services, which fell to $95.2 million from $121.3 million, attributed to the sale of BioReference's lab operations in September 2024 and lower clinical test volumes. However, revenue from the transfer of intellectual property and other sources increased by 42% to $18.7 million, bolstered by contributions from the BARDA contract and royalties from NGENLA (Somatrogon).
In terms of profitability, OPKO reported an operating income of $48.1 million for the quarter, a significant improvement compared to an operating loss of $14.2 million in the prior year. This turnaround was aided by a substantial gain of $101.6 million from the sale of certain BioReference assets to Labcorp, which closed in September 2025. The company's total costs and expenses decreased by 35% to $103.6 million, reflecting cost reductions in selling, general, and administrative expenses, as well as lower costs associated with the divested operations.
The company also noted strategic developments, including the completion of the Oncology Transaction, which provided a cash influx of $192.5 million, and the expansion of its pharmaceutical pipeline through collaborations with Pfizer and Merck. OPKO's diagnostics segment, primarily through BioReference, continues to focus on growth and new product integration, including the 4Kscore prostate cancer test. The company has also been actively managing its operational costs, resulting in a reduction of its employee headcount and other expenses.
As of September 30, 2025, OPKO reported cash, cash equivalents, and restricted cash totaling approximately $428.9 million. The company has been utilizing its cash reserves to fund operations and strategic initiatives, including a stock repurchase program that has seen approximately $73.8 million spent on repurchasing shares since its inception. Looking ahead, OPKO remains focused on advancing its product development programs and maintaining its market position, while also navigating the complexities of foreign currency exchange risks and interest rate fluctuations that could impact its financial performance.
About OPKO HEALTH, INC.
OPKO Health is a diversified healthcare company specializing in pharmaceuticals, diagnostics, and biologics. It develops and commercializes therapies like long-acting growth hormone (NGENLA) and treatments for kidney disease, while operating diagnostic labs and advanced biotech pipelines. Its core markets include the U.S., Europe, Asia, and Latin America, leveraging proprietary technologies, strategic partnerships, and a global footprint to address unmet medical needs in endocrinology, oncology, infectious diseases, and personalized medicine.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.